Daily Medication Pearl: Basaglar (Insulin Glargine)

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Medication Pearl of the Day: Basaglar (Insulin Glargine)

Indication: Basaglar is a long-acting basalhuman insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.


  • Dosing: Individualized dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use.
  • Dosage forms: Injection 100 units/mL (U-100) is available as 3 mL single-patient use Basaglar KwikPen and 3 mL single-patient-use Basaglar Tempo Pen.
  • Adverse events: Adverse reactions commonly (>5%) associated with insulin glargine products are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.
  • Mechanism of action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.
  • Manufacturer: Eli Lilly


- (lilly.com)

basaglar image - Google Search

Related Videos
© 2023 MJH Life Sciences

All rights reserved.